Full Text View
Tabular View
No Study Results Posted
Related Studies
Hormonal Contraception and Risk of Chlamydia and Gonorrhea
This study has been terminated.
Study NCT00091728   Information provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First Received: September 16, 2004   Last Updated: November 4, 2005   History of Changes
This Tabular View shows the required WHO registration data elements as marked by

September 16, 2004
November 4, 2005
September 1997
 
 
Complete list of historical versions of study NCT00091728 on ClinicalTrials.gov Archive Site
 
 
 
Hormonal Contraception and Risk of Chlamydia and Gonorrhea
Hormonal Contraception, Cervical Ectopy, and STDs

There are biological reasons to suspect that hormones may affect the risk of a woman becoming infected with a sexually transmitted disease. The evidence on this issue to date is mixed and previous studies have methodologic flaws making it difficult to draw conclusions about the results.

This study compares the risk of developing either Chlamydial or Gonorrheal infection among three groups of women: those using combined oral contraceptives (birth control pills); those using the injectable hormone (brand name Depo Provera); and those women using non-hormonal contraceptive methods.

The study was designed to examine the relationship between hormonal contraceptive use and possible increased risk of Chlamydial and Gonococcal sexually transmitted infections, and to determine if any increased risk appeared to be mediated by the extent of cervical ectopy.

Eight hundred and nineteen women, ages 15 to 45 years, were recruited from an inner city clinic and from a nearby suburban clinic. The women were classified into three groups based on type of contraceptive used. One group used oral contraceptives; the second used injectable depo-medroxyprogesterone acetate (DMPA); and the third group used non-hormonal contraceptive methods. Women from each group were followed at 3, 6, and 12 months after enrollment to determine if a new infection with Chlamydia or Gonorrhea had occurred and to evaluate the extent of cervical ectopy present.

Phase IV
Observational
Natural History, Longitudinal, Defined Population, Prospective Study
  • Chlamydia Infection
  • Neisseriaceae Infection
  • Drug: Depo Medroxyprogesterone acetate
  • Drug: Combined oral contraceptives
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Terminated
1200
August 2001
 

Inclusion Criteria:

  • Female age 15 to 45 years
  • no hormone use at enrollment
  • not pregnant or planning pregnancy

Exclusion Criteria:

  • Cervical cancer presently or in history
  • hysterectomy, cone biopsy, or cervical cryotherapy
Female
15 Years to 45 Years
Yes
 
 
 
 
NCT00091728
 
 
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
 
Principal Investigator: Charles Morrison, Ph.D. Family Health International, RTP, N.C.
Principal Investigator: Paul Blumenthal, M.D. Maryland Planned Parenthood
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
September 2004

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.